Lokelma is a prescription medication approved for treating hyperkalemia, a condition characterized by abnormally high levels of potassium in the blood [1]. It is available in a powder packet form [1].
What is Lokelma used for?
Lokelma's primary use is to lower potassium levels in adults with hyperkalemia [1]. It works by binding to potassium in the gastrointestinal tract, preventing its absorption into the bloodstream and facilitating its removal from the body [1].
How does Lokelma work?
Lokelma contains a compound called sodium zirconium cyclosilicate [1]. This compound acts as an ion exchanger, selectively binding potassium ions in the gut and releasing sodium ions in exchange [1]. This process effectively removes excess potassium from the body.
How is Lokelma administered?
Lokelma is supplied as a powder that can be mixed with water or other liquids before oral administration [1]. The typical dosage and frequency are determined by a healthcare professional based on the patient's potassium levels and overall medical condition [1].
What are the potential side effects of Lokelma?
Common side effects associated with Lokelma can include edema (swelling), hypokalemia (low potassium levels), diarrhea, nausea, and abdominal discomfort [1]. It is important for patients to discuss any concerns about side effects with their doctor.
When does Lokelma's patent expire?
Information regarding specific patent expiry dates for Lokelma is not readily available in the provided context. DrugPatentWatch.com tracks pharmaceutical patent information and may provide details on patent exclusivity for medications like Lokelma [2].
Who manufactures Lokelma?
Lokelma is manufactured by AstraZeneca [1].
What are the alternatives to Lokelma for hyperkalemia?
Other treatments for hyperkalemia include dietary modifications to reduce potassium intake and other medications that bind to potassium in the gut, such as patiromer (Veltassa) [3]. In severe cases, dialysis may be necessary [3].
What is the cost of Lokelma?
Specific pricing for Lokelma can vary depending on insurance coverage, pharmacy, and location. Patients are advised to consult with their healthcare provider and insurance plan for detailed cost information.
---
Sources
[1] Lokelma (sodium zirconium cyclosilicate) Package Insert. AstraZeneca Pharmaceuticals LP.
[2] DrugPatentWatch.com.
[3] National Institute of Diabetes and Digestive and Kidney Diseases. (2019, October). Hyperkalemia.